Circulating ghrelin levels in patients with various upper gastrointestinal diseases. 2005

Hajime Isomoto, and Hiroaki Ueno, and Yoshito Nishi, and Toru Yasutake, and Kenji Tanaka, and Naoko Kawano, and Ken Ohnita, and Yohei Mizuta, and Kenichiro Inoue, and Masamitsu Nakazato, and Shigeru Kohno
Second Department of Internal Medicine, Nagasaki University School of Medicine, Nagasaki, Japan. hajimei2002@yahoo.co.jp

The stomach is the main source of circulating ghrelin. Plasma concentrations of this hormone in patients with various upper gastrointestinal diseases remain undetermined. Thus we measured plasma ghrelin levels by radioimmunoassay in 225 subjects, including 134 Helicobacter pylori-infected and 91 uninfected subjects. They included 67 patients with chronic gastritis (CG), 26 with benign gastric polyp (BGP), 24 with gastric ulcer (GU), 24 with reflux esophagitis (RE), 18 with duodenal ulcer (DU), 28 with acute gastritis (AG), 23 with gastric cancer (GC), and 39 who had normal mucosa on upper endoscopy (N). Plasma pepsinogen I and II levels were also measured. The extent of gastritis was assessed endoscopically. Ghrelin levels differed significantly among the different disease groups. Plasma ghrelin concentrations were lowest in the CG group, followed by the GU group, and highest in the AG patients. There was a significant difference in the levels between differentiated and undifferentiated GC. Ghrelin concentrations in BGP, RE, and DU patients were comparable to those in the N group. Ghrelin circulating levels were lower in H. pylori-positive than -negative individuals, but the significant differences among disease groups were still observed in H. pylori-infected and uninfected populations. Ghrelin concentrations correlated positively with plasma pepsinogen I levels and I/II ratios and inversely with the extent of H. pylori-related gastritis. Plasma ghrelin levels varied widely in diverse conditions of the upper digestive tract, reflecting the inflammatory and atrophic events of the background gastric mucosa. Further investigation is warranted to unravel the mechanisms of the high circulating ghrelin levels in certain upper gastrointestinal diseases.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D005755 Gastrins A family of gastrointestinal peptide hormones that excite the secretion of GASTRIC JUICE. They may also occur in the central nervous system where they are presumed to be neurotransmitters. Gastrin
D005767 Gastrointestinal Diseases Diseases in any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM. Cholera Infantum,Gastrointestinal Disorders,Functional Gastrointestinal Disorders,Gastrointestinal Disorders, Functional,Disease, Gastrointestinal,Diseases, Gastrointestinal,Functional Gastrointestinal Disorder,Gastrointestinal Disease,Gastrointestinal Disorder,Gastrointestinal Disorder, Functional
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune

Related Publications

Hajime Isomoto, and Hiroaki Ueno, and Yoshito Nishi, and Toru Yasutake, and Kenji Tanaka, and Naoko Kawano, and Ken Ohnita, and Yohei Mizuta, and Kenichiro Inoue, and Masamitsu Nakazato, and Shigeru Kohno
November 2003, The American journal of gastroenterology,
Hajime Isomoto, and Hiroaki Ueno, and Yoshito Nishi, and Toru Yasutake, and Kenji Tanaka, and Naoko Kawano, and Ken Ohnita, and Yohei Mizuta, and Kenichiro Inoue, and Masamitsu Nakazato, and Shigeru Kohno
March 2006, Gut,
Hajime Isomoto, and Hiroaki Ueno, and Yoshito Nishi, and Toru Yasutake, and Kenji Tanaka, and Naoko Kawano, and Ken Ohnita, and Yohei Mizuta, and Kenichiro Inoue, and Masamitsu Nakazato, and Shigeru Kohno
October 2002, The Journal of clinical endocrinology and metabolism,
Hajime Isomoto, and Hiroaki Ueno, and Yoshito Nishi, and Toru Yasutake, and Kenji Tanaka, and Naoko Kawano, and Ken Ohnita, and Yohei Mizuta, and Kenichiro Inoue, and Masamitsu Nakazato, and Shigeru Kohno
July 2003, The Journal of clinical endocrinology and metabolism,
Hajime Isomoto, and Hiroaki Ueno, and Yoshito Nishi, and Toru Yasutake, and Kenji Tanaka, and Naoko Kawano, and Ken Ohnita, and Yohei Mizuta, and Kenichiro Inoue, and Masamitsu Nakazato, and Shigeru Kohno
January 1986, Klinicheskaia khirurgiia,
Hajime Isomoto, and Hiroaki Ueno, and Yoshito Nishi, and Toru Yasutake, and Kenji Tanaka, and Naoko Kawano, and Ken Ohnita, and Yohei Mizuta, and Kenichiro Inoue, and Masamitsu Nakazato, and Shigeru Kohno
July 1985, Clinical nuclear medicine,
Hajime Isomoto, and Hiroaki Ueno, and Yoshito Nishi, and Toru Yasutake, and Kenji Tanaka, and Naoko Kawano, and Ken Ohnita, and Yohei Mizuta, and Kenichiro Inoue, and Masamitsu Nakazato, and Shigeru Kohno
November 2004, Journal of cardiovascular pharmacology,
Hajime Isomoto, and Hiroaki Ueno, and Yoshito Nishi, and Toru Yasutake, and Kenji Tanaka, and Naoko Kawano, and Ken Ohnita, and Yohei Mizuta, and Kenichiro Inoue, and Masamitsu Nakazato, and Shigeru Kohno
February 2003, The Journal of clinical endocrinology and metabolism,
Hajime Isomoto, and Hiroaki Ueno, and Yoshito Nishi, and Toru Yasutake, and Kenji Tanaka, and Naoko Kawano, and Ken Ohnita, and Yohei Mizuta, and Kenichiro Inoue, and Masamitsu Nakazato, and Shigeru Kohno
March 2004, European journal of endocrinology,
Hajime Isomoto, and Hiroaki Ueno, and Yoshito Nishi, and Toru Yasutake, and Kenji Tanaka, and Naoko Kawano, and Ken Ohnita, and Yohei Mizuta, and Kenichiro Inoue, and Masamitsu Nakazato, and Shigeru Kohno
August 2003, European journal of endocrinology,
Copied contents to your clipboard!